Automatic detection of subsequence anomalies (i.e., an abnormal waveform denoted by a sequence of data points) in time series is critical in a wide variety of domains. However, most existing methods for subsequence anomaly detection often require knowing the length and the total number of anomalies in time series. Some methods fail to capture recurrent subsequence anomalies due to using only local or neighborhood information for anomaly detection. To address these limitations, in this paper, we propose a novel graph-represented time series (GraphTS) method for discovering subsequence anomalies. In GraphTS, we provide a new concept of time series graph representation model, which represents both recurrent and rare patterns in a time series. Particularly, in GraphTS, we develop a new 2D time series visualization (2Dviz) method, which compacts all 1D time series patterns into a 2D spatial temporal space. The 2Dviz method transfers time series patterns into a higher-resolution plot for easier sequence anomaly recognition (or detecting subsequence anomalies). Then, a Graph is constructed based on the 2D spatial temporal space of time series to capture recurrent and rare subsequence patterns effectively. The represented Graph also can be used to discover single and recurrent subsequence anomalies with arbitrary lengths. Experimental results demonstrate that the proposed method outperforms the state-of-the-art methods in terms of accuracy and efficiency.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431630 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0290092 | PLOS |
Transpl Infect Dis
December 2024
Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Introduction: With reports of expanding epidemiology of blastomycosis across the United States, the purpose of this study was to evaluate the incidence and outcomes associated with blastomycosis in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.
Methods: We conducted a retrospective case series of adult SOT and HCT recipients at a tertiary care medical center between January 1, 2005 and September 30, 2023. Cases were defined as culture-proven blastomycosis.
Int Urol Nephrol
December 2024
Department of Urology, Unidade Local de Saúde de Santo António, Centro Hospitalar Universitário Do Porto, 8th floor, Largo Do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Introduction: The primary aim of stone treatment is to achieve stone-free status. Residual fragments can cause stone growth, recurrence, urinary tract infections, and ureteric obstruction. Our goal was to describe the natural history of stone burden after retrograde intrarenal surgery (RIRS) based on stone-free status (SFS), evaluating stone growth and stone-events.
View Article and Find Full Text PDFInt Urol Nephrol
December 2024
Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Purpose: With the increasing demand for dialysis, there is a growing emphasis on patient-centered care. This study investigated patients' satisfaction levels with peritoneal dialysis (PD) and hemodialysis (HD) care in Iran.
Methods: A cross-sectional multicenter study was conducted among 346 patients with chronic kidney disease (CKD) covered by the Iran Health Insurance Organization who received dialysis services from October to December 2022 across the country.
Stress
December 2025
Technology Transfer and Innovation-Support Office, North-West University, Potchefstroom, South Africa.
Background: Self-reported mental stress is not consistently recognized as a risk factor for stroke. This prompted development of a novel algorithm for stress-phenotype indices to quantify chronic stress prevalence in relation to a modified stroke risk score in a South African cohort. The algorithm is based on biomarkers adrenocorticotrophic hormone, high-density lipoprotein cholesterol, high-sensitive cardiac-troponin-T, and diastolic blood pressure which exemplifies the stress-ischemic-phenotype index.
View Article and Find Full Text PDFJ Addict Dis
December 2024
Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved for insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce MA use by targeting substance use risk factors, including insomnia, stress, cue reactivity, and craving.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!